⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of SISCAPA Assay Technologies, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
SISCAPA Assay Technologies, Inc.
↗Washington, DC, USA
SISCAPA Assay Technologies (SAT) is a biotechnology company specializing in high-sensitivity protein quantitation using its proprietary immuno-mass spectrometry platform. The company's technology combines antibody-based peptide enrichment with quantitative mass spectrometry to provide precise, reproducible measurements of therapeutic drugs, drug targets, and biomarkers in complex biological samples.
Founded in 2011, the company serves the pharmaceutical, biotechnology, and clinical diagnostic sectors. Its workflows are used to support drug development, clinical trials, and personalized medicine by enabling longitudinal health monitoring and accurate protein analysis from various sample types, including dried blood spots.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2011
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$3.56M
PIPELINE
Stage:Commercial
Lead Drug Stage:N/A (Technology Platform)
Modalities:Proteomics, Mass Spectrometry
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Biognosys (Strategic collaboration for end-to-end proteomics services), Waters Corporation (Licensing and assay development), Crucial Data Solutions (Partnership for clinical data)
COMPETITION
Position:Niche Player
Competitors:Olink Proteomics, SomaLogic, Thermo Fisher Scientific, SCIEX
LEADERSHIP
Key Executives:
Leigh Anderson - CEO & Founder
Terry Pearson - CSO & Co-Founder
Scientific Founders:Leigh Anderson, Terry Pearson, Constance Seniff
LINKS
Website:siscapa.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with SISCAPA Assay Technologies, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.